PET Imaging of Brain Amyloid Using [11C]MeS-IMPY - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
Official Title ^†	PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
Brief Summary	Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography (PET) and a research drug called [11C]MeS-IMPY.
Detailed Description	Alzheimer's disease (AD) is characterized pathologically by the presence of beta-amyloid plaques in brain. A substantial body of research indicates that the presence of increased beta -amyloid peptide is neurotoxic, and may initiate further pathology observed in AD including neurofibrillary tangles, synaptic loss and dysfunction, and neurodegeneration. There are multiple binding sites available on beta-amyloid plaques. Three clearly identified sites are Congo-red type, Thioflavin-T type, and FDDNP type. Radioligands currently under development using positron emission tomography (PET) for studying beta-amyloid in clinical research or drug development are based on Thioflavin-T site, such as [11C]PIB and [11C]SB-13. Though variously effective, these radioligands have one or more drawbacks with respect to measuring relative regional beta-amyloid densities. Therefore, we have recently developed [11C]MeS-IMPY as an alternative radioligand for imaging beta-amyloid, which will allow a more accurate quantification of amyloid plaques in AD brain. In the current protocol, we wish to evaluate [11C]MeS-IMPY in both healthy subjects and AD patients to determine the kinetics of brain imaging beta-amyloid plaques in AD patients.
Study Phase
Study Type ^†	Interventional
Study Design ^†	Treatment
Primary Outcome Measure ^†
Secondary Outcome Measure ^†
Condition ^†	Alzheimer's Disease Healthy
Intervention ^†	Drug: [11C]MeS-IMPY
MEDLINE PMIDs	11734604, 9374364, 12368666
Links

Recruitment Information Fields
Recruitment Status ^†	Completed
Enrollment ^†	30
Start Date ^†	December 2006
Completion Date	November 2008
Eligibility Criteria ^†	INCLUSION CRITERIA: Healthy control subjects aged 18-90 years and AD patients aged 50-90, with history/physical exam, ECG, and laboratory tests. Informed Consent. AD Patients: Mini-Mental State Examination (score greater than or equal to 10). AD Patients: Meet NINCDS-ADRDA criteria for probable AD. EXCLUSION CRITERIA: Current or prior history of any alcohol or drug abuse. Severe systemic disease based on history and physical exam. Positive result on urine screen for illicit drugs. Laboratory tests with clinically significant abnormalities. Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits. Pregnancy or breast feeding. Claustrophobia. Presence of ferromagnetic metal in the body or heart pacemaker. History of brain disease other than Alzheimer's disease. Unable to lay on one's back for the PET/MRI scan.
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	Yes
Contacts ^††
Location Countries ^†	United States

Administrative Information Fields
NCT ID ^†	NCT00407576
Organization ID	070036
Secondary IDs ^††	07-M-0036
Study Sponsor ^†	National Institute of Mental Health (NIMH)
Collaborators ^††
Investigators ^†
Information Provided By	National Institutes of Health Clinical Center (CC)
Verification Date	November 2008
First Received Date ^†	December 2, 2006
Last Updated Date	November 8, 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.